{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-002326","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.406688+00:00","generated_at":"2026-05-28T05:58:50.496682+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M","bullets":["Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).","Annualized Q4 production output ~103% of estimated $30M/year capacity; backlog fell to $4.4M from $9.4M.","Contract manufacturer submitted response to FDA inspection observations; company filed Non-Administrative NADA for Re-Tain® in January.","Conference call to discuss full unaudited results on February 26, 2025 at 9:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-002326","json":"https://secwatch.observer/filing/0001213900-25-002326.json","markdown":"https://secwatch.observer/filing/0001213900-25-002326.md","text":"https://secwatch.observer/filing/0001213900-25-002326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/0001213900-25-002326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025002326/ea0227158-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:58:50.496682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}